Melanotan 2 (MT-II) is a synthetic cyclic heptapeptide modeled on alpha-melanocyte-stimulating hormone (α-MSH), the body's own signal for triggering pigment production in the skin. Unlike the natural hormone, Melanotan 2 is non-selective — it activates several melanocortin receptors at once, which is what gives it both its tanning effects and its other documented actions on sexual response and energy metabolism.
It was originally developed as a research tool to explore whether stimulating melanin production could provide protection against UV-induced skin damage without sun exposure. Along the way, researchers noticed it produced two other striking effects: spontaneous penile erections and changes in appetite and thermogenesis (heat production by metabolic tissue). These observations turned MT-II into one of the more widely studied melanocortin agonists, and led directly to the development of bremelanotide, an FDA-approved cousin designed specifically for sexual dysfunction.
Melanotan 2 sits at an interesting crossroads in peptide research — a single small molecule that touches pigmentation, sexual function, and metabolism through a shared receptor family. That breadth has made it scientifically useful, and also explains why its side-effect profile is more eventful than many peptides.
Melanotan 2 and Skin Pigmentation
Melanotan 2's primary and original use case is sunless tanning. By activating melanocortin-1 receptors on pigment-producing cells in the skin, it stimulates the production of eumelanin — the dark pigment responsible for tanning — without requiring UV exposure. The effect is dose-dependent and cumulative, with skin darkening developing over days to weeks of repeated dosing.
Because of demand for this effect, Melanotan 2 has been widely sold through unregulated online channels, which has created its own set of issues. Analytical work using LC-UV-MS/MS testing examined vials purchased from three internet sources and found that actual peptide content ranged from 4.32 to 8.84 mg per vial despite all vendors claiming 10 mg, with some lots containing 4–6% unknown impurities (3). For anyone evaluating Melanotan 2, source quality and third-party testing matter enormously — the molecule itself is well-characterized, but the supply chain often is not.
The synthesis of Melanotan 2 has been worked out as a 12-step solution-phase process producing >90% pure peptide, and more recent chemistry work has explored stapled analogues with sub-nanomolar receptor binding affinity, suggesting next-generation melanocortin agonists are actively being developed (5, 7).
Melanotan 2 and Sexual Response
One of the most consistent and well-documented effects of Melanotan 2 is its action on erectile function. Studies investigating MT-II delivered through multiple routes — intravenous, intrathecal, directly into the paraventricular nucleus of the hypothalamus, and intracavernosal — show that it dose-dependently induces erectile events and shortens the latency to the first erection (6). It also amplifies erections triggered by direct cavernous nerve stimulation, indicating both an inducer effect (starting erections on its own) and a facilitator effect (potentiating natural erectile signaling).
The mechanism appears to involve both central and peripheral melanocortin pathways. Selective nerve transection experiments showed that the facilitator effect survives spinal cord transection and pelvic or dorsal penile nerve cuts — but is abolished by removing the lumbar sympathetic chain, pointing to sympathetic nervous system involvement (6). This finding is part of why melanocortin agonists became serious candidates for treating erectile dysfunction, and led directly to bremelanotide (a closely related variant) receiving FDA approval for hypoactive sexual desire disorder.
Melanotan 2 and Metabolism and Thermogenesis
Beyond skin and sexual function, melanocortin signaling plays a role in how the body regulates energy expenditure and brown adipose tissue activity — the metabolically active fat that generates heat. Research using MT-II as a probe of this system has shown that it can partially rescue impaired thermogenic capacity in subjects deficient in pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide involved in regulating sympathetic nerve activity to brown fat (8).
In these studies, three weeks of MT-II treatment during cold acclimation restored noradrenaline-induced metabolic rate and corrected deficits in lipid mobilization in response to adrenergic stimulation. The interpretation is that PACAP acts upstream of melanocortin receptors in the pathway that drives heat production from brown adipose tissue, and that activating those receptors directly can compensate for upstream signaling defects (8). This is why melanocortin agonists are being explored as potential metabolic and anti-obesity tools — though Melanotan 2 itself is too non-selective and too eventful in its side-effect profile to be a serious therapeutic candidate for that purpose.